trending Market Intelligence /marketintelligence/en/news-insights/trending/0v7MLuia8UBEEEQWsLFsWA2 content esgSubNav
In This List

Eton Pharmaceuticals' injectable hypotension drug gets US FDA nod

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Eton Pharmaceuticals' injectable hypotension drug gets US FDA nod

Eton Pharmaceuticals Inc. received the U.S. Food and Drug Administration's approval for Biorphen to treat low blood pressure caused by the dilation of blood vessels due to anesthesia intake.

Biorphen, which is an injectable form of phenylephrine, can be administered without diluting, thus reducing the risk of medication errors waste caused due to overdrawing medication, Eton Pharmaceuticals said in an Oct. 22 press release.

Phenylephrine, which is a highly concentrated medication primarily used for its drying effect to increase blood pressure, is required to be manually diluted before a patient can have it. It could also be purchased from 503B compounding pharmacies, but because compounded drugs are not subjected to FDA review, they are often associated with higher risks of medication error, the company said.

Before the Deer Park, Ill.-based company received the regulator's approval, phenylephrine was the only approved medication available for lowering the anesthesia-induced low blood pressure.

Eton Pharmaceuticals CEO Sean Brynjelsen said the company plans to make Biorphen available to hospitals across the U.S. before 2019 end.